Cyclophosphamide versus Placebo in Scleroderma Lung Disease

Key Points

• Assess the therapeutic efficacy and durability of one year of oral cyclophosphamide compared to placebo in patients with symptomatic scleroderma-related interstitial lung disease.
• Evaluated oral cyclophosphamide versus placebo administered over a 1-year treatment period in patients with symptomatic scleroderma-related interstitial lung disease.
• Tracked changes in lung function, dyspnea, skin thickening, and health-related quality of life across a 24-month total study duration.
• One year of oral cyclophosphamide produced a statistically significant but modest beneficial effect on lung function, dyspnea, skin thickening, and health-related quality of life.
• Improvements in lung function achieved during the 1-year treatment course were sustained through the 24 months of follow-up.